文献速递支持与姑息治疗

Naldemedine治疗癌症患者阿片类药物所致便秘的随机III期及扩展研究

Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
PubMed 文献 · J Clin Oncol · 2017-10-02

COMPOSE-4为2周随机双盲安慰剂对照研究,COMPOSE-5为12周开放扩展研究。癌症OIC患者随机接受每日口服Naldemedine 0.2 mg或安慰剂,主要终点为SBM应答率。Naldemedine组SBM应答率显著高于安慰剂组,总体耐受性良好。

要点

  • Naldemedine 0.2 mg每日一次显著提高癌症OIC患者的SBM应答率。
  • 最常见治疗中出现的不良事件为腹泻。
  • 未观察到阿片戒断症状,对阿片镇痛无明显影响。

核心结论

  • 每日口服Naldemedine 0.2 mg可有效治疗癌症患者的阿片类药物所致便秘,且总体耐受性良好。

研究设计与样本

  • III期试验包括2周随机双盲安慰剂对照研究(COMPOSE-4)和12周开放标签扩展研究(COMPOSE-5)。
  • COMPOSE-4纳入193例符合条件的癌症OIC成人患者,按1:1随机分配至Naldemedine 0.2 mg每日一次口服(n=97)或安慰剂(n=96)。
  • COMPOSE-5的主要终点为安全性。

主要发现

  • COMPOSE-4中Naldemedine组SBM应答率为71.1%(69/97),安慰剂组为34.4%(33/96),P < .0001。
  • Naldemedine组较安慰剂组每周SBM频率变化为5.16 vs 1.54(P < .0001)。
  • Naldemedine组较安慰剂组每周完全排空SBM变化为2.76 vs 0.71(P < .0001)。
  • Naldemedine组较安慰剂组每周无用力排便SBM变化为3.85 vs 1.17(P = .0005)。
  • COMPOSE-4中Naldemedine组治疗中出现的不良事件报告率为44.3%(43/97),安慰剂组为26.0%(25/96),P = .01;COMPOSE-5中131例患者有105例(80.2%)报告治疗中出现的不良事件。

关键数值与推荐

  • COMPOSE-4主要终点为SBM应答者比例,定义为每周SBM≥3次且较基线增加≥1次/周。
  • COMPOSE-4中Naldemedine组腹泻报告率为19.6%(19/97),安慰剂组为7.3%(7/96);COMPOSE-5中Naldemedine组腹泻报告率为18.3%(24/131)。

临床怎么用

  • 对于癌症伴阿片类药物所致便秘的患者,可考虑每日口服Naldemedine 0.2 mg以改善排便。
  • 用药期间需关注腹泻等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Opioid-induced constipation (OIC) is a frequent and debilitating adverse effect (AE) of opioids-common analgesics for cancer pain. We investigated the efficacy and safety of a peripherally acting μ-opioid receptor antagonist, naldemedine (S-297995), for OIC, specifically in patients with cancer. Patients and Methods This phase III trial consisted of a 2-week, randomized, double-blind, placebo-controlled study (COMPOSE-4) and an open-label, 12-week extension study (COMPOSE-5). In COMPOSE-4, eligible adults with OIC and cancer were randomly assigned on a 1:1 basis to receive once-daily oral naldemedine 0.2 mg or placebo. The primary end point was the proportion of spontaneous bowel movement (SBM) responders (≥ 3 SBMs/week and an increase of ≥ 1 SBM/week from baseline). The primary end point of COMPOSE-5 was safety. Results In COMPOSE-4, 193 eligible patients were randomly assigned to naldemedine (n = 97) or placebo (n = 96). The proportion of SBM responders in COMPOSE-4 was significantly greater with naldemedine than with placebo (71.1% [69 of 97 patients] v 34.4% [33 of 96 patients]; P < .0001). A greater change from baseline was observed with naldemedine than with placebo in the frequency of SBMs/week (5.16 v 1.54; P < .0001), SBMs with complete bowel evacuation/week (2.76 v 0.71; P < .0001), and SBMs without straining/week (3.85 v 1.17; P = .0005). In COMPOSE-4, more patients treated with naldemedine than with placebo reported treatment-emergent AEs (TEAEs) (44.3% [43 of 97 patients] v 26.0% [25 of 96 patients]; P = .01); in COMPOSE-5, 105 (80.2%) of 131 of patients reported TEAEs. Diarrhea was the most frequently reported TEAE in COMPOSE-4 (19.6% [19 of 97 patients] v 7.3% [seven of 96 patients] with naldemedine v placebo) and COMPOSE-5 (18.3% [24 of 131 patients] with naldemedine). Naldemedine was not associated with signs or symptoms of opioid withdrawal and had no notable impact on opioid-mediated analgesia. Conclusion Once-daily oral naldemedine 0.2 mg effectively treated OIC and was generally well tolerated in patients with OIC and cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Katakami N, Harada T, Murata T, et al. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. J Clin Oncol. 2017. PMID: 28968171. doi:10.1200/JCO.2017.73.0853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。